Fate Therapeutics
FATE
182 hedge funds and large institutions have $401M invested in Fate Therapeutics in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 22 closing their positions.
142% more call options, than puts
Call options by funds: $116K | Put options by funds: $48K
73% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 22
16% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 49
9% more funds holding
Funds holding: 167 → 182 (+15)
16.69% less ownership
Funds ownership: 124.12% → 107.43% (-17%)
56% less capital invested
Capital invested by funds: $904M → $401M (-$503M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$5.98M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.94M |
| 3 |
D.E. Shaw & Co
New York
|
+$5.9M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$5.25M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$18.8M |
| 2 |
Holocene Advisors
New York
|
-$18.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.6M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.51M |
FATE Hedge Fund Activity: Q2 2024 in Review
182 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2024, worth a combined $401M — down 56% from $904M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new FATE positions and 22 closed out — a net gain of 16 holders — while 57 added to existing stakes and 49 trimmed.
The largest buyer was Deerfield Management, adding an estimated $5.98M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $18.8M sold.
- 182 institutional investors held Fate Therapeutics (FATE) as of Q2 2024, up from 167 in Q1 2024.
- Funds reported $401M of Fate Therapeutics stock for Q2 2024, down 56% quarter-over-quarter.
- 38 funds opened new Fate Therapeutics positions in Q2 2024 and 22 closed out, a net change of +16 holders.
- The largest Fate Therapeutics buyer in Q2 2024 was Deerfield Management, an estimated $5.98M added.
- The largest Fate Therapeutics seller in Q2 2024 was Suvretta Capital Management, an estimated $18.8M sold.
Based on aggregated 13F filings for Q2 2024.